Registration 333-299144
Underwriters: StoneX Financial Inc.
Company research
Regenlab USA Inc.
CIK 2084031Updated Oct 29, 2026
Filing activity
Latest filing
3 filings on record · FWP, S-1/A, S-1.
About the company
RegenLab is a science-driven regenerative medicine company originally founded in Switzerland and now structured under RegenLab USA, Inc., our U.S.-based holding entity. We operate through a fully integrated platform with three manufacturing sites and dedicated R&D and clinical teams based in New Jersey (USA), Paris (France), and Monthey (Switzerland). Across these sites, we maintain full control of the development and industrialization cycle, including GMP manufacturing, clinical and regulatory affairs, and global IP management. RegenLab is the holder of over 70 granted patents, covering proprietary blood-processing devices (Platelet Rich Plasma, or “PRP”), crosslinked scaffolds, combination products (PRP with Hyaluronic Acid (“HA”)), bone marrow–derived solutions, and bioengineered matrices designed for point-of-care preparation and safe, reproducible use across outpatient and surgical settings.
Offerings
Filing attachments
regenlabusa_ex107.htm · S-1/A · 2026-10-27
Exhibit 107 333-299144 Calculation of Filing Fee Table S-1 (Form Type) N/A RegenLab USA, Inc. (Exact Name of Registrant as Specified in its Charter) Security Type Security Fee Amount Proposed Proposed Fee Amount of to be …
Read attachment ↗regenlabusa_ex4-1.htm · S-1/A · 2026-10-27
Exhibit 4.1 THE REGISTERED HOLDER OF THIS REPRESENTATIVE COMMON STOCK PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS REPRESENTATIVE COMMON STOCK PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS REPRESENTATIVE COMMON STOCK PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS REPRESENTATIVE COMMON STOCK PURCHASE WARRANT OR CAUSE IT TO BE THE SUBJECT OF ANY HEDGING, SHORT SALE, DERIV…
Read attachment ↗regenlabusa_ex99-1.htm · S-1/A · 2026-10-27
Exhibit 99.1 REGENLAB USA, INC. FORM OF AUDIT COMMITTEE CHARTER Adopted: [ ], 2026 I. Purpose. The purpose of the Audit Committee (the “Committee”) of the Board of Directors (the “Board”) of RegenLab USA, Inc., a Delaware corporation (the “Company”), is to assist the Board with oversight of the Company’s accounting and financial reporting processes and the audit of the Company’s financial statements. The primary role of the Committee is to oversee the Company’s financial reporting and dis…
Read attachment ↗regenlabusa_ex99-2.htm · S-1/A · 2026-10-27
Exhibit 99.2 REGENLAB USA, INC. FORM OF COMPENSATION COMMITTEE CHARTER Adopted: [ ], 2026 I. Purpose The Compensation Committee (“ Committee ”) of the Board of Directors (“ Board ”) of RegenLab USA, Inc., a Delaware corporation (“ Company ”), is appointed by the Board to: (a) assist the Board in discharging its responsibilities relating to the compensation of the Company’s directors and executive officers; and (b) produce an annual report on executive officer compensation for inclusion in …
Read attachment ↗regenlabusa_ex107.htm · S-1 · 2026-09-25
Exhibit 107 Calculation of Filing Fee Table S-1 (Form Type) N/A RegenLab USA, Inc. (Exact Name of Registrant as Specified in its Charter) Security Type Security Fee Amount Proposed Proposed Fee Amount of to be …
Read attachment ↗